MedTrace Logo

Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components

NCT04377945 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2024-06-17

No results posted yet for this study

Summary

This is a two-part, double-blind, placebo-controlled, randomized, multicenter Phase 2 clinical trial of JM-010 in patients with Parkinson's Disease.

Conditions

  • Dyskinesias
  • Parkinson Disease

Interventions

DRUG

Part 1, JM-010 component Group A

JM-010 component Group A

DRUG

Part 1, JM-010 component Group B

JM-010 component Group B

DRUG

Part 1, JM-010 component Group C

JM-010 component Group C

DRUG

Part 1, Placebo Group

Placebo Group

DRUG

Part 2, JM-010 combination Group A

JM-010 combination Group A

DRUG

Part 2, JM-010 combination Group B

JM-010 combination Group B

DRUG

Part 2, JM-010 component Group C

JM-010 component Group C

DRUG

Part 2, Placebo Group

Placebo Group

Sponsors & Collaborators

  • Bukwang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Sooyeon Park · Bukwang Pharmaceutical

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-28
Primary Completion
2024-02-14
Completion
2024-02-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04377945 on ClinicalTrials.gov